BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 4, 2026 is 265.60. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 76.48 — a change of 247.28% (higher).

EV/EBIT

265.60

YoY

247.28%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of BrightGene Bio-Medical Technology Co is 2025 265.60 . EV/EBIT (Enterprise Value to EBIT) of BrightGene Bio-Medical Technology Co was 2024 76.48 . It decreases by 247.28% higher compared to the previous year.

The BrightGene Bio-Medical Technology Co EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
152.66 CNY
Jan 1, 2020
92.11 CNY
Jan 1, 2021
69.91 CNY
Jan 1, 2022
72.48 CNY
Jan 1, 2023
75.64 CNY
Jan 1, 2024
76.48 CNY
Jan 1, 2025
265.60 CNY
Jan 1, 2026 (e)
39.57 CNY
The BrightGene Bio-Medical Technology Co EV/EBIT history
YEAREV/EBITYoY
est39.57-85.10%
265.60+247.28%
76.48+1.11%
75.64+4.36%
72.48+3.68%
69.91-24.10%
92.11-39.66%
152.66-30.93%
221.03-34.85%
339.25-66.97%
1,026.98—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BrightGene Bio-Medical Technology Co Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides BrightGene Bio-Medical Technology Co's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates BrightGene Bio-Medical Technology Co's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots BrightGene Bio-Medical Technology Co's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if BrightGene Bio-Medical Technology Co grows earnings faster than its peers.

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

EV/EBIT (Enterprise Value to EBIT) of BrightGene Bio-Medical Technology Co is 265.60 in 2025.

EV/EBIT (Enterprise Value to EBIT) of BrightGene Bio-Medical Technology Co changed from 76.48 to 265.60, representing a 247.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s BrightGene Bio-Medical Technology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — BrightGene Bio-Medical Technology Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — BrightGene Bio-Medical Technology Co